TNBC的指南针：用细胞地图导航预后

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2025-07-17 DOI:10.1016/j.ccell.2025.06.017

Yi-Fan Zhou, Ding Ma, Zhi-Ming Shao

{"title":"TNBC的指南针：用细胞地图导航预后","authors":"Yi-Fan Zhou, Ding Ma, Zhi-Ming Shao","doi":"10.1016/j.ccell.2025.06.017","DOIUrl":null,"url":null,"abstract":"In this issue of <em>Cancer Cell</em>, Meyer et al. use imaging mass cytometry and identify a stem-like basoluminal tumor cell linked to poor prognosis in triple-negative breast cancer (TNBC). They integrate this finding with T cell spatial architecture to establish a five-subtype classification for predicting prognosis and guiding therapy.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"676 1","pages":""},"PeriodicalIF":48.8000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"TNBC’s compass: Navigating prognosis with a cellular map\",\"authors\":\"Yi-Fan Zhou, Ding Ma, Zhi-Ming Shao\",\"doi\":\"10.1016/j.ccell.2025.06.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this issue of <em>Cancer Cell</em>, Meyer et al. use imaging mass cytometry and identify a stem-like basoluminal tumor cell linked to poor prognosis in triple-negative breast cancer (TNBC). They integrate this finding with T cell spatial architecture to establish a five-subtype classification for predicting prognosis and guiding therapy.\",\"PeriodicalId\":9670,\"journal\":{\"name\":\"Cancer Cell\",\"volume\":\"676 1\",\"pages\":\"\"},\"PeriodicalIF\":48.8000,\"publicationDate\":\"2025-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Cell\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ccell.2025.06.017\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ccell.2025.06.017","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在这一期的《Cancer Cell》杂志上，Meyer等人利用成像细胞术发现了一种与三阴性乳腺癌（TNBC）预后不良相关的茎样基底管肿瘤细胞。他们将这一发现与T细胞的空间结构结合起来，建立了一个预测预后和指导治疗的五亚型分类。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

TNBC’s compass: Navigating prognosis with a cellular map

In this issue of Cancer Cell, Meyer et al. use imaging mass cytometry and identify a stem-like basoluminal tumor cell linked to poor prognosis in triple-negative breast cancer (TNBC). They integrate this finding with T cell spatial architecture to establish a five-subtype classification for predicting prognosis and guiding therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.